Legend Biotech LEGN
$15.25 −$0.85 (-5.28%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $15.44 +1.25%
Open$15.95
Prev close$16.10
Day range$15.15 – $16.13
Volume3.42M
Market cap$2.96B
P/E (TTM)–
Dividend yield–
LEGN Stock News
Headlines matching Legend Biotech or the LEGN ticker, most recent first.
- H.C. Wainwright Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $65
- RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $58
- Barclays Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $74 Negative
- UBS Maintains Legend Biotech(LEGN.US) With Hold Rating, Maintains Target Price $28
- A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $24 to $48
- A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $24 to $65
- Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Legend Biotech (LEGN) and Sagimet Biosciences, Inc. Class A (SGMT)
- Analysts Have Conflicting Sentiments on These Healthcare Companies: Intuitive Surgical (ISRG), Legend Biotech (LEGN) and Mineralys Therapeutics, Inc. (MLYS)
- RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $63 Negative
- RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $59 Negative
- UBS Downgrades Legend Biotech(LEGN.US) to Hold Rating, Cuts Target Price to $28 Negative
- Goldman Sachs Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $40.5 Negative
- Barclays Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $80
- J.P. Morgan Downgrades Legend Biotech(LEGN.US) to Hold Rating, Cuts Target Price to $35 Negative
- UBS Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $49
No comments yet — be the first to weigh in on LEGN.
Sign in to join the discussion.